Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017168 (gastroesophageal reflux disease)
 11,783 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Approximately two thirds of pregnant patients develop heartburn. The origin is multifactorial, but the predominant factor is a decrease in LES pressure caused by female sex hormones, especially progesterone. Mechanical factors play a small role. Serious reflux complications during pregnancy are rare; therefore EGD and other diagnostic tests are infrequently needed. Symptomatic GERD during pregnancy should be managed with a step-up algorithm beginning with lifestyle modifications and dietary changes. Antacids or sucralfate are considered the first-line medical therapy. If symptoms persist, H2RAs should be used. Ranitidine is probably preferred because of its documented efficacy and safety profile in pregnancy, even in the first trimester. Proton-pump inhibitors are reserved for the woman with intractable symptoms or complicated reflux disease. Lansoprazole may be the preferred PPI because of its safety profile in animals and case reports of safety in human pregnancies.
 ...
PMID:Gastroesophageal reflux disease during pregnancy. 1263 18

The frequency, symptoms, and complication rate of PUD seem to decrease during pregnancy. Yet clinicians often have to treat dyspepsia or pyrosis of undetermined origin during pregnancy because the frequency of pyrosis significantly increases during pregnancy, and clinicians reluctantly perform EGD during pregnancy for pyrosis to differentiate reliably between GERD and PUD. Dyspepsia or pyrosis during pregnancy is initially treated with dietary and lifestyle modifications. If the symptoms do not remit with these modifications, sucralfate or antacids, preferably magnesium-containing or aluminum-containing antacids, should be administered. Histamine2 receptor antagonists are recommended when symptoms are refractory to antacid or sucralfate therapy. Ranitidine seems to be a relatively safe H2 receptor antagonist. If symptoms continue despite H2 receptor antagonist therapy, the patient should be evaluated for possible EGD or PPI therapy. Pregnant women with hemodynamically significant upper gastrointestinal bleeding or other worrisome clinical findings should undergo EGD. Indications for surgery include ulcer perforation, ongoing active bleeding from an ulcer requiring transfusion of six or more units of packed erythrocytes, gastric outlet obstruction refractory to intense medical therapy, and a malignant gastric ulcer without evident metastases.
 ...
PMID:Gastric and duodenal ulcers during pregnancy. 1263 19

After a careful revision of the various papers and on the basis of their personal experience, the persons responsible for this project analyse the factors that, today, influence the development of an adenocarcinoma in the region of the gastro-esophageal junction. They also study therapeutic strategies on the basis of new findings in anatomic-physiological matters of this region. From this analysis, specialists notice an increase in adenocarcinomas which affect the gastric region of the cardia, in comparison with carcinomas which affects the gastric region in toto. By considering Barrett, Hayward, Riedel and Ruol's studies, they maintain that the fundamental factor which causes the development of cardial adenocarcinoma is the gastroesophageal reflux. This reflux acts as a chronic irritative stimulus on the esophageal wall and therefore it provokes an increase in mucous secretion and the formation of metaplasia. This metaplasia is initially mucosecreting, acid-secreting and in the end it becomes intestinal. This also leads to the appearance of absorbent calciform cells; the absorption of toxic or mutagenic substance for the cell itself, will be the next step for the development of an adenocarcinoma. Nowadays the therapy of intestinal metaplasia provides for different therapeutic levels: from the endoscopic monitoring (which is used for the most serious cases of dysplasia), to the PPI medical treatment(today in disuse), to the surgical laparoscopic treatment with non-refluxing plasty (Nissen, Toupet). This last treatment is today associated with endoscopic esophageal mucosectomy in order to achieve a better effectiveness. This happens through the use of various methodologies, for example the multipolar electrocoagulation.
 ...
PMID:[Predisposing factors for development of cardial adenocarcinoma]. 1269 93

The Gatekeeper Reflux Repair System is a new, promising endoscopic anti-reflux therapy. It has now been shown that it is possible to implant hydrogel prosthesis in the submucosa of the esophagus of humans. The pilot study in humans showed that it is a safe technique and no prostheses migrated into the mediastinum. With the help of endoscopic ultrasonography, each prosthesis was followed during the 6-month pilot study. After finishing this pilot study, new multi-center studies have been initiated with implantation of more prostheses to increase efficacy. One of the definite advantages over the other endoscopic treatments currently being developed is its reversibility. Regarding endoscopic anti-reflux therapy in general, it is important to stress that at this time no data are available in the literature about the comparison to medical therapy. At the same time long-term results are also unknown. For these reasons these endoscopic procedures must be considered experimental and they should be performed in a clinical research setting. Within a few years the role of the Gatekeeper Reflux Repair System will be better understood for those PPI-dependent GERD-patients who wish to stop their medication.
 ...
PMID:Gatekeeper Reflux Repair System: technique, pre-clinical, and clinical experience. 1279 37

Noncardiac chest pain is a heterogeneous condition for which diagnosis and treatment are challenging. Research is needed to streamline evaluation to minimize unnecessary invasive testing and costs. Chest pain clinics to assess chest pain patients are popular in the United States and may be of value in reassuring patients and reducing presentation to hospital; however, recently this has been contended [111]. Options for the effective treatment of NCCP are dependent on the risk of an adverse outcome and the cost-effectiveness of the management algorithm that is followed. Most (64%) of those presenting to the emergency department with chest pain are classified as having NCCP [112,113]. GERD is probably the most important cause and application of a test of acid suppression with a high-dose PPI for 1 to 2 weeks seems to be a useful diagnostic tool. In those patients with GERD-related NCCP, short-term and potentially long-term therapy with a PPI (commonly higher than standard dose) is required to alleviate symptoms. Esophageal dysmotility is relatively uncommon in patients with NCCP and evaluation by esophageal manometry might be limited to rule out achalasia. Chest wall syndromes are common but probably often missed. Many patients with NCCP have psychologic or psychiatric abnormalities, as either the cause or an effect of the chest pain, but diagnosis here depends on techniques not applied easily in the acute situation. Pain modulators seem to offer significant improvement in chest pain symptoms for non-GERD-related NCCP. Finally, trials of management strategies to deal with this problem are required urgently, because the earlier discharge of patients with NCCP may exacerbate the problem. Fig. 2 provides a flow chart for diagnosis and treatment of NCCP.
 ...
PMID:Noncardiac chest pain: evaluation and treatment. 1285 5

GERD is a condition affecting patients throughout the 24-hour period, although the nighttime interval may require special consideration because of the pharmacologic profile of the agents used to treat GERD, and the normal physiologic processes rendering nighttime GERD particularly damaging. GERD patients should be managed with appropriate therapy proportional to the frequency and severity of their symptoms. PPIs are the most potent inhibitors of acid secretion, and with a thorough knowledge of their pharmacologic properties, clinicians can be helped in identifying strategies that can maximize the benefits of their potency (see Table 2). PPIs offer significant benefit to persons requiring longer-term therapy because they are potent agents and offer ease of dosing and favorable drug interaction and adverse effect profiles. However, it is necessary that clinicians understand the physiology and pharmacology of acid secretion to use them appropriately. Inevitably, proper therapeutic treatment demands that variables such as pharmacokinetics, ethnicity (metabolic profile), and the normal physiology of acid secretion be considered when choosing an appropriate PPI.
 ...
PMID:Managing gastroesophageal reflux disease: from pharmacology to the clinical arena. 1455 34

The primary treatment goals in patients with gastroesophageal reflux disease are relief of symptoms, prevention of symptom relapse, healing of erosive esophagitis, and prevention of complications of esophagitis. In patients with reflux esophagitis, treatment is directed at acid suppression through the use of lifestyle modifications (e.g., elevating the head of the bed, modifying the size and composition of meals) and pharmacologic agents (a histamine H2-receptor antagonist [H2RA] taken on demand or a proton pump inhibitor IPPI] taken 30 to 60 minutes before the first meal of the day). The preferred empiric approach is step-up therapy (treat initially with an H2RA for eight weeks; if symptoms do not improve, change to a PPI) or step-down therapy (treat initially with a PPI; then titrate to the lowest effective medication type and dosage). In patients with erosive esophagitis identified on endoscopy, a PPI is the initial treatment of choice. Diagnostic testing should be reserved for patients who exhibit warning signs (i.e., weight loss, dysphagia, gastrointestinal bleeding) and patients who are at risk for complications of esophagitis (i.e., esophageal stricture formation, Barrett's esophagus, adenocarcinoma). Antireflux surgery, including open and laparoscopic versions of Nissen fundoplication, is an alternative treatment in patients who have chronic reflux with recalcitrant symptoms. Newer endoscopic modalities, including the Stretta and endocinch procedures, are less invasive and have fewer complications than antireflux surgery, but response rates are lower.
 ...
PMID:Management of gastroesophageal reflux disease. 1456 83

This brief overview explored the major medication therapies available for the treatment of GERD and gastric ulcers. These therapeutic agents have helped millions of people manage significant symptoms that negatively impact quality of life. A few words of caution are required when caring for the patient with GERD or ulcer disease. The CNS cannot conclude in the absence of symptoms that pathology does not exist. For each patient's plan, consider the risks and benefits of referral for diagnostic testing. Barium swallow or endoscopy may provide an invaluable benefit for diagnosis, monitoring responses to therapy, and may provide early identification of cellular abnormalities. Finally, in combination therapies (such as PPI and H2 antagonists), scheduling of doses is critical to achieve the best outcomes. Patients and families may need assistance of the CNS in designing a functional dosing schedule congruent with the demands of their lifestyles to achieve the best results.
 ...
PMID:Gastric ulcers and GERD: the new "plagues" of the 21st century update for the clinical nurse specialist. 1498 31

After a cardiac source has been excluded, the most likely cause of NCCP is GERD. Clinical history often cannot make the diagnosis of GERD-related NCCP. The PPI test is a simple, highly sensitive, and cost-effective tool that should be the first diagnostic test used in evaluating these patients. Patients with GERD-related NCCP require long-term therapy with a PPI,commonly double the standard dose. The introduction of the wireless pH system and the multi-channel intraluminal impedance will help us to further understand the role of GERD in NCCP. Treatment of NCCP has dramatically improved since the introduction of the PPI class of drugs.However, better therapeutic modalities should be sought out to further improve our current treatment of GERD-related NCCP.
 ...
PMID:Gastroesophageal reflux disease in noncardiac chest pain. 1506 36

NCCP is a common condition in Asia. The diagnostic approach of NCCP in Asians is similar to the Western population. GERD is the most common etiology. PPI therapy is an attractive alternative to other invasive diagnostic tests for NCCP and is equally effective for the Asian population.
 ...
PMID:Noncardiac chest pain: an Asian view. 1506 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>